Description
Prostaglandin E1 (PGE1) is an endogenous prostaglandin synthesized from linolenic acid. PGE1 is clinically used for its vasodilatory activity as a treatment for erectile dysfunction. PGE1 also exhibits nephroprotective and pro-angiogenic activities. PGE1 decreases small intestine mucosa lesions in animal models of intestinal ischemia/reperfusion. PGE1 also improves renal function in subject with renal dysfunction or renal failure. Additionally, PGE1 enhances VEGF production in animal models of ischemia.
References
Hanchanale V, Eardley I. Alprostadil for the treatment of impotence. Expert Opin Pharmacother. 2014 Feb;15(3):421-8. PMID: 24369066.
Brasileiro JL, Inoye CM, Aydos RD, et al. Ischemia and reperfusion of rat small intestine using pentoxyfilline and prostaglandin E1. Acta Cir Bras. 2013 Nov;28(11):767-73. PMID: 24316743.
Liu WJ, Zhang BC, Guo R, et al. Renoprotective effect of alprostadil in combination with statins in patients with mild to moderate renal failure undergoing coronary angiography. Chin Med J (Engl). 2013;126(18):3475-80. PMID: 24034093.
Inoue H, Aihara M, Tomioka M, et al. Specific enhancement of vascular endothelial growth factor (VEGF) production in ischemic region by alprostadil--potential therapeutic application in pharmaceutical regenerative medicine. J Pharmacol Sci. 2013;122(2):158-61. PMID: 23728380.